Whitehawk Therapeutics (WHWK) Income from Continuing Operations (2010 - 2026)
Whitehawk Therapeutics' (WHWK) quarterly Income from Continuing Operations came in at 22194000.0 in Q1 2026, down 130.4% year-on-year from 73016000.0 in Q1 2025, and up 24.26% on a QoQ basis from 29304000.0 in Q4 2025.
Whitehawk Therapeutics (WHWK) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 17 years of Income from Continuing Operations data on file, last reported at 22194000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 130.4% year-over-year to 22194000.0 in Q1 2026; TTM through Mar 2026 was 124933000.0, a 532.98% decrease from a year earlier, with the FY2025 full-year figure at 16271000.0, up 74.45% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 22194000.0, up from 29304000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for WHWK reached as high as 73016000.0 in Q1 2025 and fell as low as 55200000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 14240941.18 across 5 years, with a median of 16269000.0 in 2023.
- Across the five-year window, Income from Continuing Operations plunged 1089.39% in 2022 and jumped 471.15% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 13913000.0 in 2022, then declined by 16.93% to 16269000.0 in 2023, then increased by 4.84% to 15482000.0 in 2024, then slumped by 89.28% to 29304000.0 in 2025, then advanced by 24.26% to 22194000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 22194000.0 in Q1 2026, 29304000.0 in Q4 2025, and 18235000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Whitehawk Therapeutics | 34.18 Mn | 34.18 Mn | - | -22.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.19 Mn |
| Dec 31, 2025 | -29.30 Mn |
| Sep 30, 2025 | -18.24 Mn |
| Jun 30, 2025 | -55.20 Mn |
| Mar 31, 2025 | 73.02 Mn |
| Dec 31, 2024 | -15.48 Mn |
| Sep 30, 2024 | -12.80 Mn |
| Jun 30, 2024 | -15.88 Mn |
| Mar 31, 2024 | -19.67 Mn |
| Dec 31, 2023 | -16.27 Mn |
| Sep 30, 2023 | -16.30 Mn |
| Jun 30, 2023 | -17.97 Mn |
| Mar 31, 2023 | -15.29 Mn |
| Dec 31, 2022 | -13.91 Mn |
| Sep 30, 2022 | -14.47 Mn |
| Jun 30, 2022 | -18.27 Mn |
| Mar 31, 2022 | -13.86 Mn |
| Dec 31, 2021 | -15.99 Mn |
| Sep 30, 2021 | -87.09 Mn |
| Jun 30, 2021 | -1.54 Mn |